Program
HS-20110
A development code. Also written as “HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.” and “HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.”.
Its studies are led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since Feb 24, 2025 | Feb 24, 2025 | Dec 31, 2026phase 1 · NCT06892379 |
- Named in hoffmann la roche’s own pipeline as
RG6975 CDH17 ADC (Hansoh)
, phase 1, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Hoffmann-La Roche.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2025First study: phase 1 study in Solid TumorsFirst studyNCT06892379 · 631 planned · United States, China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Solid TumorsNCT06892379
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06892379Solid Tumors · United States, China | 1 | Recruiting | Dec 31, 2026 | 631 |
How it is read
Names in the registry
- “HS-20110”, 2 entries
- “HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.”, 1 entry
- “HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.”, 1 entry
Codes read as this program: HS20110.
Conditions, from the studies’ own filings
First seen by our ledger Nov 21, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.